Revolution Medicines Inc (OQ:RVMD)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 700 Saginaw Dr
REDWOOD CITY CA 94063-4752
Tel: N/A
IR: See website
Key People
Mark A. Goldsmith
Chairman of the Board, President, Chief Executive Officer
Steve Kelsey
President of Research and Development
Margaret A. Horn
Chief Operating Officer, General Counsel
Jack Lee Anders
Vice President - Finance and Principal Accounting Officer
Business Overview
Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company's pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.
Financial Overview
For the nine months ended 30 September 2020,Revolution Medicines Inc revenues decreased 10% to $34.2M.Net loss applicable to common stockholders increased 77% to$76.2M. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Higher net loss reflects Research anddevelopment - Balancing val increase of 45% to $91.8M(expense).
Employees: 117 as of Sep 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $2,224M as of Sep 30, 2020
Annual revenue (TTM): $46.32M as of Sep 30, 2020
EBITDA (TTM): -$92.48M as of Sep 30, 2020
Net annual income (TTM): -$95.02M as of Sep 30, 2020
Free cash flow (TTM): -$88.96M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 66,380,190 as of Nov 9, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.